Pfizer

Pfizer Inc. (NYSE:PFE) to Post Q1 2023 Earnings of $0.72 Per Share, Jefferies Financial Group Forecasts

/ / Health Care / ,

Jefferies Financial Group lowered their Q1 2023 earnings estimates for shares of Pfizer in a note issued to investors on Friday, March 17th. Jefferies Financial Group analyst A. Tewari now anticipates that the biopharmaceutical company will post earnings per share of $0.72 for the quarter, down from their previous estimate of $0.78. Jefferies Financial Group has a “Hold” rating and a $43.00 price objective on the stock.

Pfizer Inc. (NYSE:PFE) to Post Q1 2023 Earnings of $0.72 Per Share, Jefferies Financial Group Forecasts Read Post »

Pfizer (NYSE:PFE) reported Q4 2022 Revenues of $24.3 Billion，update 2023 financial guidance

/ / Health Care /

January 31, 2023 — Pfizer Inc. (NYSE:PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance. Pfizer Inc. (NYSE:PFE) reported Q4 adjusted earnings  of $1.14 per diluted share, up from $0.79 a year earlier. Analysts polled by Capital IQ expected $1.04. Revenue for the quarter was $24.29 billion, up from $23.84 billion a year earlier. Analysts surveyed by Capital IQ expected $24.40 billion. The company said it is expecting fiscal 2023 adjusted earnings of $3.25 to $3.45 per diluted share. Analysts polled by Capital IQ are expecting $4.38. Revenue for the year is expected to range between $67 billion and $71 billion. Analysts surveyed by Capital IQ are expecting $74.23 billion. Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth，Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 5% Operationally。 Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth，Excluding Contributions

Pfizer (NYSE:PFE) reported Q4 2022 Revenues of $24.3 Billion，update 2023 financial guidance Read Post »

Pfizer (NYSE:PFE) to acquire Seagen (NASDAQ:SGEN) for $43 billion

/ / Health Care / ,

Pfizer Inc (NYSE:PFE) said Monday it agreed to buy biotech company Seagen Inc (NASDAQ:SGEN) for $43 billion to bolster its cancer treatment program. The New York-based drugmaker said it would pay $229 a share in cash, a nearly 33 percent premium to Seagen’s closing price of $172.61 on Friday. Seagen is headquartered in Bothel, Washington. Pfizer said it expects to fund most of the acquisition through $31 billion of new long-term debt, with the rest coming from short-term financing and cash on hand. Pfizer said it expects the deal with Seagen to have a neutral to slightly higher impact on adjusted earnings per share in the third to fourth full year after closing, and said it expects to achieve cost efficiencies of nearly $1 billion in the third full year.

Pfizer (NYSE:PFE) to acquire Seagen (NASDAQ:SGEN) for $43 billion Read Post »

Pfizer (NYSE:PFE) intends to acquire Seagen (NASDAQ:SGEN) for $229 per share in cash

/ / Health Care / ,

Pfizer (NYSE:PFE) will reportedly acquire Seagen (NASDAQ:SGEN) for $43 billion in total enterprise value for $229 per share in cash. Seagen’s risk-adjusted revenue contribution is expected to exceed $10 billion in 2030. Pfizer expects to finance the transaction primarily through a new borrowing of $31 billion of long-term debt, with the remainder coming from short-term financing and cash on hand.

Pfizer (NYSE:PFE) intends to acquire Seagen (NASDAQ:SGEN) for $229 per share in cash Read Post »

Bank of America Securities: Lowered Pfizer (NYSE:PFE) price target to $50 with neutral rating

/ / Health Care / ,

Bank of America Securities released a research report saying that Pfizer’s (NYSE:PFE) guidance for this year’s results indicates that the company expects pandemic-related revenue to decline by more than 60%, resulting in total revenue falling about 30% from the middle of the guidance. The bank said that while it was not surprised by the slowdown in demand, the magnitude of the decline and profit margins affected EPS guidance. Non-COVID-related revenues were also weaker, partially offset by poor performance on the Ibrance and Eliquis franchises. The bank believes investors have been focusing on non-COVID-related businesses given the uncertainty surrounding growth prospects in the post-pandemic period. The report mentioned that Pfizer highlighted several upcoming products that may improve investor sentiment. However, the bank believes they are unlikely to ease growth concerns. The bank continues to be cautious about the group’s long-term growth prospects, with revenue expected to grow at a CAGR of

Bank of America Securities: Lowered Pfizer (NYSE:PFE) price target to $50 with neutral rating Read Post »

Scroll to Top